Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort.

TitleDefining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort.
Publication TypePublication
AuthorsStott-Miller M, Müllerová H, Miller B, Tabberer M, Baou CEl, Keeley T, Martinez FJ, Han ML, Dransfield M, Hansel NN, Cooper CB, Woodruff P, Ortega VE, Comellas AP, Iii RPaine, Kanner RE, Anderson W, M Drummond B, Kim V, Tal-Singer R, Lazaar AL
JournalInt J Chron Obstruct Pulmon Dis
Date Published2020
KeywordsBronchitis, Chronic, Female, Humans, Male, Mucus, Pulmonary Disease, Chronic Obstructive, quality of life, Respiratory Function Tests, Surveys and Questionnaires

BACKGROUND: Chronic cough and phlegm are frequently reported chronic obstructive pulmonary disease (COPD) symptoms. Prior research classified chronic mucus hypersecretion (CMH) based on the presence of these symptoms for ≥3 months, called chronic bronchitis (CB) if respiratory infection symptoms were present for 1-2 years (Medical Research Council [MRC] definition). We explored whether the COPD Assessment Test (CAT), a simple measure developed for routine clinical use, captures CMH populations and outcomes similarly to MRC and St. George's Respiratory Questionnaire (SGRQ) definitions.METHODS: We identified CMH in the SPIROMICS COPD cohort using (a) MRC definitions, (b) SGRQ questions for cough and phlegm (both as most/several days a week), and (c) CAT cough and phlegm questions. We determined optimal cut-points for CAT items and described exacerbation frequencies for different CMH definitions. Moderate exacerbations required a new prescription for antibiotics/oral corticosteroids or emergency department visit; severe exacerbations required hospitalization. Results were stratified by smoking status.RESULTS: In a population of 1431 participants (57% male; mean FEV% predicted 61%), 47% and 49% of evaluable participants had SGRQ- or CAT-defined CMH, respectively. A cut-point of ≥2 for cough and phlegm items defined CMH in CAT. Among SGRQ-CMH+ participants, 80% were also defined as CMH+ by the CAT. CMH+ participants were more likely to be current smokers. A higher exacerbation frequency was observed for presence of CMH+ versus CMH- in the year prior to baseline for all CMH definitions; this trend continued across 3 years of follow-up, regardless of smoking status.CONCLUSION: Items from the CAT identified SGRQ-defined CMH, a frequent COPD trait that correlated with exacerbation frequency. The CAT is a short, simple questionnaire and a potentially valuable tool for telemedicine or real-world trials. CAT-based CMH is a novel approach for identifying clinically important characteristics in COPD that can be ascertained in these settings.

Alternate JournalInt J Chron Obstruct Pulmon Dis
PubMed ID33116463
PubMed Central IDPMC7568676
Grant ListK24 HL137013 / HL / NHLBI NIH HHS / United States
P30 DK054759 / DK / NIDDK NIH HHS / United States
P30 ES005605 / ES / NIEHS NIH HHS / United States
U01 HL137880 / HL / NHLBI NIH HHS / United States
Manuscript Full Title: 
Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort.
Manuscript Status: 
Published and Public